Allograft recipients

Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001 72 1199-1205. 

Sirolimus is a calcineurin inhibitor that acts as an immunosuppressant. It is administered systemically in the prophylaxis of organ rejection in kidney allograft recipients. It may be used in combination with ciclosporin, particularly initially. However since ciclosporin is markedly nephrotoxic, when sirolimus is used with ciclosporin, monitoring of kidney function is essential. 

In heart allograft recipients, the onset of newly diagnosed CMV disease occurred after treatment with IV ganciclovir was stopped at day 28 post-transplant, suggesting that continued dosing may be necessary to prevent late occurrence of CMV disease in this patient population. 

Hepatotoxicity Hepatotoxicity with elevated serum alkaline phosphatase and bilirubin may occur primarily in allograft recipients. Periodically measure serum transaminases, alkaline phosphatase and bilirubin for early detection of hepatotoxicity. 

Eason, ID., S.L. Wee,T. Kawai, H.Z. Hong, I Powelson, M. Widmer, and A.B. Cosimi, Recombinant human dimeric tumor necrosis factor receptor (TNFR Fc) as an immunosuppressive agent in renal allograft recipients. Transplant Proc, 1995. 27(1) 554. 

Barone, G., C.T. Chang, M.G. Choc, Jr., et al.. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group. Transplantation, 1996.61(6) 875-80. 

Bistrup C, Nielsen FT, Jeppesen UE, Dieperink H. Effect of grapefruit juice on Sandimmun Neoral absorption among stable renal allograft recipients. Nephrol Dial Transplant 2001 16(2) 373-377. 

In a 23-year-old woman, a kidney allograft recipient with recurrent lymphoceles treated with povidone-iodine irrigations (50 ml of a 1% solution bd for 6 days), a metabolic acidosis occurred and renal function deteriorated. After a few days, despite suspension of irrigation, the patient developed oliguria, and dialysis was needed. A renal biopsy showed acute tubular necrosis. 

Sanchez CP, Salem M, Ettenger RB. Changes in cyclosporine A levels in pediatric renal allograft recipients... 

Mueller, E.A. et al. (1994b) Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients-a concentration-controlled comparison with the commercial formulation. Transplantation, 57 1178-1182. 

Hetzel GR, Hermsen D, Hohlfeld T, Rettich A, Ozcan F, Fussholler A, Grabensee B, Plum J. Effects of candesartan and perindopril on renal function, TGF-P 1 plasma levels and excretion of prostaglandins in stable renal allograft recipients. Clinical Nephrology 2002, 57, 296-302. 

Nashan, B., Moore, R., Amlot, P. et al. (1997). Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350, 1193-1198. 

Naesens M, Kuypers DR, Streit F, et al. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination implications for drug exposure in renal allograft recipients. Clin Pharmacol Ther 2006 80(5) 509-521. 

Y. Vanrenterghem, L. Rods, T. Lerut, J. Gruwez, P. Michielsen, P. Gresele, et al.. Thromboembolic Complications and Haemostatic Changes in Cyclosporin- Treated Cadaveric Kidney Allograft Recipients, Lancet 1 (1985) 999-1002. 

Delmonico, F.L. Cosimi, A.B. Monoclonal antibody treatment of human allograft recipients. Surg. Gynecol. Obstet. 1988, 166, 89-98. 

Gruber SA, Gillingham K, Sothern RB, Stephanian E, Matas AJ, Dunn DL. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients. Clin Transplant 1994 8(4) 388-95. 

Joshi AS, King SY, Zajac BA, Makowka L, Sher LS, Kahan BD, Menkis AH, Stiller CR, Schaefle B, Kornhauser DM. Phase I safety and pharmacokinetic studies of brequinar sodium after single ascending oral doses in stable renal, hepatic, and cardiac allograft recipients. J Clin Pharmacol 1997 37(12) 1121-8. 

Wiener Y, Nakhleh RE, Lee MW, Escobar FS, Venkat KK, Kupin WL, Mozes MF. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome. (Tin Transplant 1997 ll(3) 157-62. 

Jacobson SH, Jaremko G, Duraj FF, Wilczek HE. Renal fibrosis in cyclosporin A-treated renal allograft recipients morphological findings in relation to renal hemodynamics. Transpl Int 1996 9(5) 492-8. 

Shed AG, Disney AP, Mathew TH, Amiss N, Excell L. Cancer development in cadaveric donor renal allograft recipients treated with azathioprine (AZA) or cyclosporine (CyA) or AZA/CyA. Transplant Proc 1991 23(1 Pt 2) 1111-12. 

Termeer A, Hoitsma AJ, Koene RA. Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporine in renal allograft recipients. Transplantation 1986 42(2) 220-1. 

Tsinahs D, Dickenmann M, Brunner F, Gurke L, Mihatsch M, Nickeleit V. Acute renal failure in a renal allograft recipient treated with intravenous immunoglobulin. Am J Kidney Dis 2002 40(3) 667-70. 

Wadhwa NK, Schroeder TJ, O Flaherty E, Pesce AJ, Myre SA, Munda R, First MR. Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient. Ther Drug Monit 1987 9(l) 123-5. 

Fisher A, Mor E, Hytiroglou P, Emre S, Boccagni P, Chodoff L, Sheiner P, Schwartz M, Thung SN, MiUer C. FK506 hepatotoxicity in liver allograft recipients. Transplantationl995 59(ll) 1631-2. 

Delmonico FL, Cosimi AB, Covlin R, et al. Murine OKT4A immunosuppression in cadaver donor renal allograft recipients a Cooperative Clinical Trials in Transplantation pilot study. Transplantation 1997 63(8) 1087-95. 

Hueso M, Bover J, Seron D, Gil-Vernet S, Sabate I, Fulladosa X, Ramos R, Coll O, Alsina J, Grinyo JM. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998 66(12) 1727-31. 

The immunogenicity and safety of pneumococcal polysaccharide vaccine have been studied in renal allograft recipients, dialysis patients (19), children and adolescents with sickle-cell anemia (SED-11, 682) (SEDA-12, 277), people with diabetes mellitus (SED-11, 682), and children with nephrotic syndrome (20). When comparing the results with healthy persons there were no significant differences. 

Min DI, Ku YM, Rayhill S, Corwin C, Wu YM, Hunsicker LG. Sudden hearing loss associated with tacrolimus in a kidney-pancreas allograft recipient. Pharmacotherapy 1999 19(7) 891-3. 

Hopp L, Lombardozzi S, Gilboa N, et al. Removal of FK 506 by continuous hemofiltration report of two allograft recipients with renal and liver failures. Clin Transplant 1993 7 546-51. 

Bradley PP, Warden GD, Maxwell JG, Rothstein G. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole. Ann Intern Med 1980 93(4) 560-2. 

---